Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication.

Geier MR, Geier DA.

Exp Biol Med (Maywood). 2003 Jun;228(6):660-4.

PMID:
12773696
2.
3.

An assessment of the impact of thimerosal on childhood neurodevelopmental disorders.

Geier DA, Geier MR.

Pediatr Rehabil. 2003 Apr-Jun;6(2):97-102.

PMID:
14534046
6.

A two-phased population epidemiological study of the safety of thimerosal-containing vaccines: a follow-up analysis.

Geier DA, Geier MR.

Med Sci Monit. 2005 Apr;11(4):CR160-70. Epub 2005 Mar 24.

PMID:
15795695
9.

Thimerosal exposure in infants and developmental disorders: a retrospective cohort study in the United kingdom does not support a causal association.

Andrews N, Miller E, Grant A, Stowe J, Osborne V, Taylor B.

Pediatrics. 2004 Sep;114(3):584-91.

PMID:
15342825
10.
11.
12.

Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases.

Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, Shinefield H, Chen RT; Vaccine Safety Datalink Team.

Pediatrics. 2003 Nov;112(5):1039-48. Erratum in: Pediatrics. 2004 Jan;113(1):184.

PMID:
14595043
13.

Thimerosal-containing vaccines: evidence versus public apprehension.

DeStefano F.

Expert Opin Drug Saf. 2009 Jan;8(1):1-4. doi: 10.1517/14740330802489748 . No abstract available.

PMID:
19236212
15.

Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data.

Parker SK, Schwartz B, Todd J, Pickering LK.

Pediatrics. 2004 Sep;114(3):793-804. Review. Erratum in: Pediatrics. 2005 Jan;115(1):200.

PMID:
15342856
16.

Simultaneous vaccination of Chinese applicants for a United States immigrant visa.

Hua L, Hongtao H, Shunqin W, Jinping G, Jiandong C, Zhaoliang L, Xinwen F.

Travel Med Infect Dis. 2008 May;6(3):130-6. doi: 10.1016/j.tmaid.2008.03.004.

PMID:
18486068
17.

Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.

Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR; Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.

Pediatrics. 2005 Aug;116(2):e285-94.

PMID:
16061582
18.

Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Pool V, Braun MM, Kelso JM, Mootrey G, Chen RT, Yunginger JW, Jacobson RM, Gargiullo PM; VAERS Team. US Vaccine Adverse Event Reporting System.

Pediatrics. 2002 Dec;110(6):e71.

PMID:
12456938
19.

Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.

Knuf M, Habermehl P, Faber J, Bock HL, Sänger R, Bogaerts H, Clemens R, Schuind A, du Prel JB, Schmitt HJ.

Vaccine. 2006 Jul 7;24(27-28):5627-36. Epub 2006 May 2.

PMID:
16740348
20.

Thimerosal exposure in infants and neurodevelopmental disorders: an assessment of computerized medical records in the Vaccine Safety Datalink.

Young HA, Geier DA, Geier MR.

J Neurol Sci. 2008 Aug 15;271(1-2):110-8. doi: 10.1016/j.jns.2008.04.002. Epub 2008 May 15.

PMID:
18482737

Supplemental Content

Support Center